Steven G Reed

Summary

Affiliation: Corixa Corporation
Country: USA

Publications

  1. ncbi Vaccines for parasitic and bacterial diseases
    Steven G Reed
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Curr Opin Immunol 15:456-60. 2003
  2. ncbi Prospects for a better vaccine against tuberculosis
    S G Reed
    Corixa Corporation, Seattle, WA 98104, USA
    Tuberculosis (Edinb) 83:213-9. 2003
  3. ncbi Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, Seattle WA 98104, USA
    J Immunol 181:7948-57. 2008
  4. ncbi Optimized subunit vaccine protects against experimental leishmaniasis
    Sylvie Bertholet
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 27:7036-45. 2009
  5. ncbi Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning
    Rhea N Coler
    The Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, United States
    Vaccine 27:223-33. 2009
  6. ncbi Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41
    Yasir A W Skeiky
    Corixa Corporation, Seattle, WA, USA
    Vaccine 23:3937-45. 2005
  7. ncbi Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection
    Vanitha S Raman
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, Washington 98104, USA
    Infect Immun 77:5623-30. 2009
  8. ncbi Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion
    Susan L Baldwin
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, United States
    Vaccine 27:5956-63. 2009
  9. ncbi Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, Washington 98104, USA
    AAPS PharmSciTech 13:498-506. 2012
  10. ncbi Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells
    Rhea N Coler
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Infect Immun 75:4648-54. 2007

Collaborators

Detail Information

Publications110 found, 100 shown here

  1. ncbi Vaccines for parasitic and bacterial diseases
    Steven G Reed
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Curr Opin Immunol 15:456-60. 2003
    ..There are indications both in animal models and in patients that vaccines may be used not only to protect but also to treat leishmania infections...
  2. ncbi Prospects for a better vaccine against tuberculosis
    S G Reed
    Corixa Corporation, Seattle, WA 98104, USA
    Tuberculosis (Edinb) 83:213-9. 2003
    ..Thus, there is renewed optimism for the potential of developing new and improved TB vaccines...
  3. ncbi Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, Seattle WA 98104, USA
    J Immunol 181:7948-57. 2008
    ..This study identified numerous novel human T cell Ags suitable to be included in subunit vaccines against tuberculosis...
  4. ncbi Optimized subunit vaccine protects against experimental leishmaniasis
    Sylvie Bertholet
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 27:7036-45. 2009
    ..This study establishes the immunogenicity and protective efficacy of the improved Leish-110f subunit vaccine antigen adjuvanted with natural (MPL-SE) or synthetic (EM005) Toll-like receptor 4 agonists...
  5. ncbi Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning
    Rhea N Coler
    The Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, United States
    Vaccine 27:223-33. 2009
    ..8 formulated in either AS02A or AS01B Adjuvant Systems. These results demonstrate that T-cell screening of the Mtb genome can be used to identify CD4+ T-cell antigens that are candidates for vaccine development...
  6. ncbi Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41
    Yasir A W Skeiky
    Corixa Corporation, Seattle, WA, USA
    Vaccine 23:3937-45. 2005
    ....
  7. ncbi Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection
    Vanitha S Raman
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, Washington 98104, USA
    Infect Immun 77:5623-30. 2009
    ....
  8. ncbi Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion
    Susan L Baldwin
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, United States
    Vaccine 27:5956-63. 2009
    ....
  9. ncbi Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, Washington 98104, USA
    AAPS PharmSciTech 13:498-506. 2012
    ....
  10. ncbi Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells
    Rhea N Coler
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Infect Immun 75:4648-54. 2007
    ..The Leish-111f+MPL-SE product we report here is the first defined vaccine for leishmaniasis in human clinical trials and has completed phase 1 and 2 safety and immunogenicity testing in normal, healthy human subjects...
  11. ncbi Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations
    Ryan C Anderson
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, WA 98104, USA
    Colloids Surf B Biointerfaces 75:123-32. 2010
    ....
  12. ncbi Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant
    Yasuyuki Goto
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 25:7450-8. 2007
    ..The results indicate that SMT/MPL-SE can be an effective vaccine candidate for use against VL...
  13. ncbi KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis
    Yasuyuki Goto
    Infectious Disease Research Institute, Seattle, Washington, USA
    Clin Vaccine Immunol 18:1118-24. 2011
    ..major, responsible for cutaneous leishmaniasis. The results demonstrate the feasibility of producing a practical, cost-effective leishmaniasis vaccine capable of protecting both humans and dogs against multiple Leishmania species...
  14. ncbi Antigen-specific T-cell responses of leprosy patients
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Clin Vaccine Immunol 15:1659-65. 2008
    ..Our results indicate several potential candidate antigens which may be useful for either leprosy diagnosis or vaccination and demonstrate the utility of leprosy WBA that can be applied broadly in clinical or field settings...
  15. ncbi Cloning of the gene encoding a protective Mycobacterium tuberculosis secreted protein detected in vivo during the initial phases of the infectious process
    Sandeep Mukherjee
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 175:5298-305. 2005
    ....
  16. ncbi Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection
    Yasuyuki Goto
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 27:2884-90. 2009
    ..Mice immunized with the SMT/MPL-SE vaccine developed significantly smaller lesions following ear challenge with L. major. These results suggest that SMT is a promising vaccine antigen for multiple forms of leishmaniasis...
  17. ncbi Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis
    R N Coler
    The Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 166:6227-35. 2001
    ..tuberculosis. Thus, these results suggest that Mtb 8.4 is a potential candidate for inclusion in a subunit vaccine against TB...
  18. ncbi The importance of adjuvant formulation in the development of a tuberculosis vaccine
    Susan L Baldwin
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 188:2189-97. 2012
    ..These results highlight the importance of properly formulating subunit vaccines with effective adjuvants for use against tuberculosis...
  19. ncbi Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay
    Lance K Ching
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, USA
    J Immunol Methods 373:54-62. 2011
    ..Overall, the QuantiGene platform is reliable, reproducible, and sensitive. These agonists have the potential to be used as adjuvant components in vaccines against various pathogens...
  20. ncbi Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant
    Rhea N Coler
    Preclinical Biology, Infectious Disease Research Institute, Seattle, Washington, United States of America
    PLoS ONE 6:e16333. 2011
    ....
  21. ncbi Serum antibodies to lipophilin B detected in late stage breast cancer patients
    Darrick Carter
    Department of Tumor Antigen Discovery, Corixa Corporation, Seattle, Washington 98104, USA
    Clin Cancer Res 9:749-54. 2003
    ..A polymorphism identified in Lipophilin B did not appear to influence human sera reactivity. The data indicate that humoral immune responses to lipophilin B may serve as a diagnostic indicator, particularly for breast cancer...
  22. ncbi Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant
    Yasir A W Skeiky
    Corixa Corporation, 1124 Columbia Street, Suite 200, Seattle, WA 98104, USA
    Vaccine 20:3292-303. 2002
    ....
  23. ncbi Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys
    Steven G Reed
    Corixa Corporation, Seattle, WA 98104, USA
    Proc Natl Acad Sci U S A 106:2301-6. 2009
    ....
  24. ncbi Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein
    Yasir A W Skeiky
    Corixa Corp, Seattle, WA 98104, USA
    J Immunol 172:7618-28. 2004
    ..tuberculosis comparable to bacillus Calmette-Guérin immunization. Mtb72F in AS02A formulation is currently in phase I clinical trial, making it the first recombinant tuberculosis vaccine to be tested in humans...
  25. ncbi Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning
    P Probst
    Corixa Corporation, Seattle, WA 98104, USA
    J Immunol 166:498-505. 2001
    ..Ags identified by T cells from immune donors might constitute potential vaccine candidates for leishmaniasis...
  26. ncbi Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease
    A Campos-Neto
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 69:4103-8. 2001
    ..The remarkable protection induced by LmSTI1 and TSA in an animal model that is evolutionarily close to humans qualifies this antigen combination as a promising candidate subunit vaccine against human leishmaniasis...
  27. ncbi Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Pharm Dev Technol 16:511-9. 2011
    ..Substitution of naturally derived egg phosphatidylcholine with synthetic 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) produced an emulsion with similar physicochemical properties and stability...
  28. ncbi Cloning, characterization, and serodiagnostic evaluation of Leishmania infantum tandem repeat proteins
    Yasuyuki Goto
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Infect Immun 74:3939-45. 2006
    ..Our results suggest that TR regions from the novel L. infantum proteins identified in this study are immunodominant B-cell epitopes and may represent good candidates for serodiagnosis of VL...
  29. ncbi Insight toward early diagnosis of leprosy through analysis of the developing antibody responses of Mycobacterium leprae-infected armadillos
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Seattle, WA 98104, USA
    Clin Vaccine Immunol 18:254-9. 2011
    ..leprae infection but also indicate considerable variability in the development of antigen-specific antibodies. Our data suggest that a combination of antigens is likely required to provide accurate and early leprosy diagnosis...
  30. ncbi A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, USA
    Sci Transl Med 2:53ra74. 2010
    ....
  31. ncbi Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    FEMS Immunol Med Microbiol 55:258-70. 2009
    ..trachomatis. Some of the vaccines prevented bacterial shedding and colonization of the upper genital tract to varying degrees by mechanisms that may include CD4+ T cells...
  32. ncbi Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs
    Yasuyuki Goto
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vet Parasitol 160:215-20. 2009
    ..In addition, we show a correlation between antibody titers to several antigens and severity of clinical symptoms during canine VL...
  33. ncbi Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate
    Hillarie Plessner Windish
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 29:7842-8. 2011
    ..ID87/GLA-SE appears to be a promising new vaccine candidate that warrants further development...
  34. ncbi P704P, P712P, and P775P: A genomic cluster of prostate-specific genes
    John A Stolk
    Corixa Corporation, Seattle, Washington 98104, USA
    Prostate 60:214-26. 2004
    ..Such understanding will likely result in the development of promising new markers for screening, diagnosis, and prognosis, as well as potential therapeutic approaches for combating this disease...
  35. ncbi Intradermal immunization improves protective efficacy of a novel TB vaccine candidate
    Susan L Baldwin
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 27:3063-71. 2009
    ..This highlights the need to explore different routes of immunization based on the adjuvant formulations used...
  36. ncbi Rational design and evaluation of a multiepitope chimeric fusion protein with the potential for leprosy diagnosis
    Malcolm S Duthie
    Protein Advances Inc, 1102 Columbia St, Seattle, WA 98104, USA
    Clin Vaccine Immunol 17:298-303. 2010
    ....
  37. ncbi Immunological dominance of Trypanosoma cruzi tandem repeat proteins
    Yasuyuki Goto
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 76:3967-74. 2008
    ..cruzi strains with regard to induced immunological responses, host susceptibility, disease outcomes, and pathogenicity...
  38. ncbi Antigen-specific cellular and humoral responses are induced by intradermal Mycobacterium leprae infection of the mouse ear
    Malcolm S Duthie
    Infectious Disease Research Institute, Suite 400, 1124 Columbia St, Seattle, WA 98104, USA
    Infect Immun 75:5290-7. 2007
    ..These results indicate the utility of intradermal ear infection for both induction and understanding of the immune response during M. leprae infection and the identification or testing of new leprosy treatments...
  39. ncbi Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice
    A Campos-Neto
    Infectious Disease Research Institute Corixa Corporation, Seattle, Washington 98104, USA
    Infect Immun 70:2828-36. 2002
    ....
  40. ncbi Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis
    J R Webb
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 66:4208-14. 1998
    ..Recombinant MTB12 protein elicited in vitro proliferative responses from the peripheral blood mononuclear cells of a number of purified protein derivative-positive (PPD+) human donors but not from PPD- donors...
  41. ncbi Development and pre-clinical assessment of a 73 kD chimeric fusion protein as a defined sub-unit vaccine for leprosy
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 31:813-9. 2013
    ..leprae-induced inflammation in mice. We are using these data to develop new vaccine initiatives for the continued and long-term control of leprosy...
  42. ncbi Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, WA 98104, United States
    Vaccine 29:9563-72. 2011
    ....
  43. ncbi Use of protein antigens for early serological diagnosis of leprosy
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Clin Vaccine Immunol 14:1400-8. 2007
    ..A serological diagnostic test capable of identifying and allowing treatment of early-stage leprosy could reduce transmission, prevent functional disabilities and stigmatizing deformities, and facilitate leprosy eradication...
  44. ncbi Development of a leishmaniasis vaccine: the importance of MPL
    Steven G Reed
    Corixa Corporation, Seattle, WA, USA
    Expert Rev Vaccines 2:239-52. 2003
    ..This vaccine has potential application in both the prevention and treatment of leishmaniasis...
  45. ncbi Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis
    Vanitha S Raman
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 185:1701-10. 2010
    ..Our data help to define a correlate of protection during active infection and indicate TLR synergy to be a potentially valuable tool in treating intracellular infections...
  46. ncbi Cloning and characterization of a gene encoding an immunoglobulin-binding receptor on the cell surface of some members of the family Trypanosomatidae
    Antonio Campos-Neto
    Infectious Disease Research Institute, Seattle, Washington, USA
    Infect Immun 71:5065-76. 2003
    ....
  47. ncbi Bioinformatic identification of tandem repeat antigens of the Leishmania donovani complex
    Yasuyuki Goto
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Infect Immun 75:846-51. 2007
    ..0070, LinJ25.1100, LinJ27.0400, and LinJ29.0110, which were from the 42 uncharacterized proteins, are also antigenic. The results suggest the validity of this approach for identifying leishmanial antigens of serological significance...
  48. ncbi Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions
    Susan L Baldwin
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 29:644-9. 2011
    ..Our results show that the addition of oil-in-water emulsion adjuvants to an, inactivated trivalent poliovirus vaccine are dose-sparing and are capable of enhancing, neutralizing antibody titers in the rat potency model...
  49. ncbi Selection of antigens and development of prototype tests for point-of-care leprosy diagnosis
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Clin Vaccine Immunol 15:1590-7. 2008
    ..A serological diagnostic test capable of identifying and allowing treatment of leprosy could reduce transmission, prevent functional disabilities and stigmatizing deformities, and facilitate leprosy eradication...
  50. ncbi A synthetic adjuvant to enhance and expand immune responses to influenza vaccines
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington, United States of America
    PLoS ONE 5:e13677. 2010
    ..These results suggest that synthetic TLR4 adjuvants can enhance the magnitude and quality of protective immunity induced by influenza vaccines...
  51. ncbi Expression and purification of immunologically reactive DPPD, a recombinant Mycobacterium tuberculosis skin test antigen, using Mycobacterium smegmatis and Escherichia coli host cells
    Chao Liu
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 600, Seattle, WA 98104, USA
    Can J Microbiol 50:97-105. 2004
    ..Because the DPPD gene is present only in the tuberculosis-complex organisms of the Mycobacterium genus, these highly purified molecules should be helpful in identifying individuals sensitized with tubercle bacilli...
  52. ncbi Potential serological use of a recombinant protein that is a replica of a Mycobacterium tuberculosis protein found in the urine of infected mice
    Sandeep Mukherjee
    Infectious Disease Research Institute, Seattle, Washington, USA
    Clin Diagn Lab Immunol 11:280-6. 2004
    ..The immediate availability of the antigen at a time point in which the patient's immune system is still competent would lead to a secondary immune response to U1 that persists for months in the patient's serum...
  53. ncbi IL-10 mediates susceptibility to Trypanosoma cruzi infection
    S G Reed
    Infectious Disease Research Institute, Seattle, WA 98109
    J Immunol 153:3135-40. 1994
    ..cruzi by the administration of neutralizing anti-IL-10 mAb. This study demonstrated an important and perhaps essential role of IL-10 in mediating in vivo susceptibility to T. cruzi infection...
  54. ncbi Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington, USA
    J Infect Dis 207:1242-52. 2013
    ....
  55. ncbi Advances and hurdles on the way toward a leprosy vaccine
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA USA
    Hum Vaccin 7:1172-83. 2011
    ..We summarize and discuss leprosy vaccine strategies that have been deployed previously and discuss those strategies that are currently being developed to augment recent breakthroughs in leprosy control...
  56. ncbi The development and clinical evaluation of second-generation leishmaniasis vaccines
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 30:134-41. 2012
    ..Finally, potential refinements and surrogate markers that could expedite the introduction of a vaccine that can limit the severity and incidence of leishmaniasis are discussed...
  57. ncbi Targeting TLRs expands the antibody repertoire in response to a malaria vaccine
    Steven R Wiley
    Imdaptive Inc, 3010 Northwest 56th Street, Seattle, WA 98107, USA
    Sci Transl Med 3:93ra69. 2011
    ....
  58. ncbi Prostein expression is highly restricted to normal and malignant prostate tissues
    Michael Kalos
    Corixa Corporation, Seattle, Washington 98104, USA
    Prostate 60:246-56. 2004
    ..A murine monoclonal antibody was developed, characterized, and used to evaluate the expression of prostein protein in prostatic, other normal tissue and tumor samples...
  59. ncbi Lateral flow immunoassay for diagnosis of Trypanosoma cruzi infection with high correlation to the radioimmunoprecipitation assay
    Raymond L Houghton
    InBios International, Inc, Seattle, WA 98104, USA
    Clin Vaccine Immunol 16:515-20. 2009
    ..2, with two additional sequences for peptide 1 and Kmp-11. The latter, when evaluated in a dipstick assay with consensus positive sera, had a sensitivity of 99.2% and a specificity of 99.1%...
  60. ncbi Second-generation vaccines against leishmaniasis
    Rhea N Coler
    The Infectious Disease Research Institute, 1124 Columbia Street, Suite 600, Seattle, WA 98104, USA
    Trends Parasitol 21:244-9. 2005
    ..In addition, several antigens have been identified and characterized that might be potential vaccine candidates. In this article, we focus on advances made with second-generation vaccines against leishmaniasis...
  61. ncbi Identification of Mycobacterium tuberculosis antigens of high serodiagnostic value
    Gregory C Ireton
    Infectious Disease Research Institute, 1124 Columbia Street, Seattle, WA 98104, USA
    Clin Vaccine Immunol 17:1539-47. 2010
    ....
  62. ncbi Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, WA 98104, USA
    Subcell Biochem 53:303-21. 2010
    ..Moreover, the formulation of TLR4 agonists has been shown to significantly affect the type and magnitude of elicited immune response. TLR4 agonists comprise a promising class of adjuvants for safe and effective vaccines...
  63. ncbi Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family
    J R Webb
    Infectious Disease Research Institute, University of Washington, Seattle, Washington, USA
    Infect Immun 66:3279-89. 1998
    ..Together, these data suggest that the TSA protein may be useful as a component of a subunit vaccine against leishmaniasis...
  64. ncbi Mass spectrometric identification of mtb81, a novel serological marker for tuberculosis
    R C Hendrickson
    Corixa Corporation, Seattle Washington 98140, USA
    J Clin Microbiol 38:2354-61. 2000
    ..Together, these results demonstrate that Mtb81 may be a promising complementary antigen for the serodiagnosis of TB...
  65. ncbi New horizons in adjuvants for vaccine development
    Steven G Reed
    Infectious Disease Research Institute, 1124 Columbia St Suite 400, Seattle, WA 98104, USA
    Trends Immunol 30:23-32. 2009
    ..In this review, we outline the current state of adjuvant research and development and how formulation parameters can influence the effectiveness of adjuvants...
  66. ncbi Taking toll: lipid A mimetics as adjuvants and immunomodulators
    David H Persing
    Corixa, Suite 200, 1124 Columbia Street, Seattle, WA 98104, USA
    Trends Microbiol 10:S32-7. 2002
    ..Novel approaches to vaccine development could benefit from taking full advantage of the effects of these compounds on innate and adaptive responses...
  67. ncbi Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, United States
    Colloids Surf B Biointerfaces 65:98-105. 2008
    ..It is shown that oil-in-water emulsions using animal-derived components can be substituted with synthetic or plant-derived materials while still exhibiting satisfactory physicochemical and biological properties...
  68. ncbi Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera
    Craig H Day
    Corixa Corporation, 1124 Columbia Street, Suite 200, Seattle, Washington, WA 98104, USA
    Oncogene 21:7114-20. 2002
    ....
  69. ncbi Effect of chemotherapy on whole-blood cytokine responses to Mycobacterium tuberculosis antigens in a small cohort of patients with pulmonary tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, 1124 Columbia Street, Ste 400, Seattle, WA 98104, USA
    Clin Vaccine Immunol 18:1378-86. 2011
    ..tuberculosis proteins during the course of TB therapy might be a promising path toward the development of a test of cure and warrants further validation in larger cohorts of pulmonary TB patients...
  70. ncbi A high-throughput methodology for identifying molecular targets overexpressed in lung cancers
    Tongtong Wang
    Department of Tumor Antigen Discovery, Corixa Corporation, Seattle, WA, USA
    Methods Mol Med 75:177-88. 2003
  71. ncbi Use of defined TLR ligands as adjuvants within human vaccines
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA, USA
    Immunol Rev 239:178-96. 2011
    ....
  72. ncbi Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays
    Yuqiu Jiang
    Corixa Corporation, 1124 Columbia Street, Suite 200, Seattle, Washington, WA 98104, USA
    Oncogene 21:2270-82. 2002
    ..These differentially expressed genes may be of potential utility as therapeutic and diagnostic targets for breast cancer...
  73. ncbi Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer
    Darrick Carter
    Department of Antigen Discovery, Corixa Corp, 1124 Columbia Street, Suite 200, Seattle, WA 98104, USA
    Biochemistry 41:6714-22. 2002
    ..This work describes the biochemistry of the mammaglobin/lipophilin B complex and lays the framework for use of this complex as a novel protein-based serological marker for breast cancer...
  74. ncbi Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells
    M R Alderson
    Department of Immunology, Corixa Corporation, Seattle, Washington 98104, USA
    J Exp Med 191:551-60. 2000
    ..9A. The direct identification of antigens using T cells from immune donors will undoubtedly be critical for the development of vaccines to several intracellular pathogens...
  75. ncbi Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis
    Y A Skeiky
    Corixa Corporation, Seattle, Washington 98104, USA
    Infect Immun 67:3998-4007. 1999
    ..MTB32A, therefore, represents a candidate for inclusion in subunit vaccine development. Finally, the possible role of MTB32 serine proteases as a virulence factor(s) during Mycobacterium spp. infection is discussed...
  76. ncbi Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family
    D C Dillon
    Corixa Corporation, Seattle, Washington 98104, USA
    Infect Immun 67:2941-50. 1999
    ..The human T-cell responses and initial animal studies provide support for further evaluation of this antigen as a possible component of a subunit vaccine for M.tuberculosis...
  77. ncbi Multiepitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in patients with treated or untreated Chagas' disease
    R L Houghton
    Corixa Corporation, Seattle, WA 98104
    J Infect Dis 181:325-30. 2000
    ..The results indicate that multiepitope antigens provide a more sensitive and specific alternative to lysate for detection of anti-T. cruzi antibodies, as required for developing blood screening assays...
  78. ncbi Association of Leishmania heat shock protein 83 antigen and immunoglobulin G4 antibody titers in Brazilian patients with diffuse cutaneous leishmaniasis
    Y A Skeiky
    Corixa Corporation, Seattle, Washington 98104, USA
    Infect Immun 65:5368-70. 1997
    ....
  79. ncbi A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen-presenting cells
    P Probst
    Infectious Disease Research Institute, Seattle, WA, USA
    Eur J Immunol 27:2634-42. 1997
    ..These immunomodulatory characteristics of LeIF might be excellent properties for a Th1-type adjuvant...
  80. ncbi A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy
    R L Houghton
    Corixa Corp, Seattle, Washington 98104, USA
    J Infect Dis 177:1339-44. 1998
    ..In contrast, most patients who clinically relapsed showed increased antibody titers to rK39. These data demonstrate the diagnostic and prognostic utility of rK39 in detecting active visceral leishmaniasis...
  81. ncbi LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile
    Y A Skeiky
    Corixa Corporation, Seattle, WA 98104, USA
    J Immunol 161:6171-9. 1998
    ..major. Thus, our results suggest the potential of LeIF as a Th1-type adjuvant and as a therapeutic and prophylactic vaccine Ag for leishmaniasis when used with other leishmanial Ags...
  82. ncbi A multi-epitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in radioimmunoprecipitation-confirmed and consensus-positive sera
    R L Houghton
    Corixa Corporation, Seattle, WA 98104, USA
    J Infect Dis 179:1226-34. 1999
    ..These studies show that peptides and recombinants containing multiple repeat epitopes are powerful tools for developing assays for T. cruzi antibody detection and have direct application in blood screening...
  83. ncbi L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma
    T Wang
    Department of Tumor Antigen Discovery, Corixa Corporation, 1124 Columbia Street, Seattle, WA 98104, USA
    Oncogene 20:7699-709. 2001
    ..These results strongly imply that L552S protein is immunogenic and suggest that it might have use as a vaccine target for lung cancer...
  84. ncbi Detection of mammaglobin in the sera of patients with breast cancer
    G R Fanger
    Corixa Corporation, Department of Antigen Discovery, Seattle, WA 98104, USA
    Tumour Biol 23:212-21. 2002
    ..Thus, mammaglobin, which is overexpressed and secreted from breast carcinoma cells, is detectable in sera of patients with breast cancer and may provide a rapid screening test for the diagnosis and management of breast cancer...
  85. ncbi L523S, an RNA-binding protein as a potential therapeutic target for lung cancer
    T Wang
    Department of Tumor Antigen Discovery, Corixa Corporation, Seattle, WA 98104, USA
    Br J Cancer 88:887-94. 2003
    ..Collectively, our studies suggest that L523S may be an important marker of malignant progression in human lung cancer, and further suggest that treatment approaches based on L523S as an immunogenic target are worthy of pursuit...
  86. ncbi A p53 homologue and a novel serine proteinase inhibitor are over-expressed in lung squamous cell carcinoma
    T Wang
    Department of Tumor Antigen Discovery, Corixa Corporation, 1124 Columbia Street, Seattle, WA 98104, USA
    Lung Cancer 34:363-74. 2001
    ....
  87. ncbi Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells
    R L Houghton
    Corixa Corporation, 1124 Columbia St, Ste 200, Seattle, WA 98104, USA
    Mol Diagn 6:79-91. 2001
    ..We used a combination of genetic subtraction, silicon DNA microarray analysis, and quantitative PCR to identify tissue- and tumor-specific genes as diagnostic targets for breast cancer...
  88. ncbi Serological expression cloning and immunological evaluation of MTB48, a novel Mycobacterium tuberculosis antigen
    M J Lodes
    Corixa Corporation, Seattle, Washington 98104, USA
    J Clin Microbiol 39:2485-93. 2001
    ..tuberculosis infection when it is combined with other known immunodominant antigens, such as the 38-kDa antigen...
  89. ncbi Serodiagnosis of human granulocytic ehrlichiosis by using novel combinations of immunoreactive recombinant proteins
    M J Lodes
    Corixa Corporation, 1124 Columbia St, Suite 200, Seattle, WA 98104, USA
    J Clin Microbiol 39:2466-76. 2001
    ..2% (23 of 27) of acute-phase patient serum samples are detected, indicating the potential of these antigens for use in the development of a rapid serologic assay for the detection of E. phagocytophila infection...
  90. ncbi Identification and characterization of prostein, a novel prostate-specific protein
    J Xu
    Corixa Corp, Seattle Washington 98104, USA
    Cancer Res 61:1563-8. 2001
    ..These results validate prostein as a prostate-specific marker with potential utility in the diagnosis and treatment of prostate cancer...
  91. ncbi Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG
    D C Dillon
    Corixa Corporation, Seattle, Washington 98104, USA
    J Clin Microbiol 38:3285-90. 2000
    ..rCFP-10 could also contribute to the development of a recombinant T-cell diagnostic test capable of detecting exposure to M. tuberculosis...
  92. ncbi Serological expression cloning of novel immunoreactive antigens of Babesia microti
    M J Lodes
    Corixa Corporation, Seattle, Washington 98104, USA
    Infect Immun 68:2783-90. 2000
    ..Western blot analysis with the resulting recombinant proteins indicated that these antigens were targets of humoral immune responses during B. microti infection in humans...
  93. ncbi ML0405 and ML2331 are antigens of Mycobacterium leprae with potential for diagnosis of leprosy
    Stephen T Reece
    IDRI, 1124 Columbia Street, Suite 400, Seattle, WA 98104, USA
    Clin Vaccine Immunol 13:333-40. 2006
    ..We suggest that ML0405 and ML2331 may have utility in serological leprosy diagnosis...
  94. ncbi Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 70:4215-25. 2002
    ....
  95. ncbi Role of adjuvants in modeling the immune response
    Darrick Carter
    Infectious Disease Research Institute, Seattle, Washington, USA
    Curr Opin HIV AIDS 5:409-13. 2010
    ..This review is intended to give an overview of recent findings on how adjuvants model the immune response to antigens with a focus on the field of vaccines for HIV...
  96. ncbi Adjuvants for cancer vaccines
    Thomas W Dubensky
    Immune Design Corporation, 1124 Columbia St, Ste 700, Seattle, WA 98104, United States
    Semin Immunol 22:155-61. 2010
    ..In this review, we examine new molecularly defined adjuvants and formulations and its application to cancer vaccines under development...
  97. ncbi Use of multiepitope polyproteins in serodiagnosis of active tuberculosis
    Raymond L Houghton
    Corixa Corporation, Seattle, Washington 98104, USA
    Clin Diagn Lab Immunol 9:883-91. 2002
    ..The data indicate that the use of multiple antigens, some of which are in a single polyprotein, can be used to facilitate the development of a highly sensitive test for M. tuberculosis antibody detection...
  98. ncbi Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes
    Barbara K Zehentner
    Corixa, 1124 Columbia St, Seattle, WA 98104, USA
    Clin Chem 48:1225-31. 2002
    ..In addition, this multigene assay could also be used to test peripheral blood and bone marrow samples...
  99. ncbi Evaluation of DPPD, a single recombinant Mycobacterium tuberculosis protein as an alternative antigen for the Mantoux test
    A Campos-Neto
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Tuberculosis (Edinb) 81:353-8. 2001
    ..Because the DPPD gene is not present in non-tuberculous bacilli, these results suggest that this molecule can be an additional tool for a more specific diagnosis of tuberculosis...
  100. ncbi Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells
    D M Lewinsohn
    Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington 98104, USA
    J Exp Med 187:1633-40. 1998
    ..The data suggest the possible use of nonpolymorphic MHC class Ib antigen presenting structures other than CD1...
  101. ncbi Adjuvants for malaria vaccines
    R N Coler
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Parasite Immunol 31:520-8. 2009
    ..In this minireview, we outline the current state of adjuvant research and development as it pertains to effective malaria vaccines...